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Enhanced microtubule-dependent trafficking and p53 nuclear
accumulation by suppression of microtubule dynamics
Abstract
The tumor suppressor protein p53 localizes to microtubules (MT) and, in response to DNA damage, is
transported to the nucleus via the MT minus-end-directed motor protein dynein. Dynein is also
responsible for MT-mediated nuclear targeting of adenovirus type 2 (Ad2). Here we show that treatment
with low concentrations of MT-targeting compounds (MTCs) that do not disrupt the MT network but
are known to suppress MT dynamics enhanced p53 nuclear accumulation, and the activation of the
p53-downstream target genes. p53 nuclear accumulation required binding of MTCs to MTs and
enhanced the induction of p53-up-regulated modulator of apoptosis (PUMA) mRNA and apoptosis on
challenging cells with the DNA-damaging drug adriamycin. Low concentrations of MTCs enhanced the
rate of movement of fluorescent Ad2 to the nucleus and increased the nuclear targeting efficiency of
Ad2. We propose that suppression of MT dynamics by low concentrations of MTCs enhances
MT-dependent trafficking toward the minus ends of MTs and facilitates nuclear targeting.
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The tumor suppressor protein p53 localizes to microtubules (MT)
and, in response to DNA damage, is transported to the nucleus via
the MT minus-end-directed motor protein dynein. Dynein is also
responsible for MT-mediated nuclear targeting of adenovirus type
2 (Ad2). Here we show that treatment with low concentrations of
MT-targeting compounds (MTCs) that do not disrupt the MT
network but are known to suppress MT dynamics enhanced p53
nuclear accumulation, and the activation of the p53-downstream
target genes. p53 nuclear accumulation required binding of MTCs
to MTs and enhanced the induction of p53-up-regulated modulator
of apoptosis (PUMA) mRNA and apoptosis on challenging cells with
the DNA-damaging drug adriamycin. Low concentrations of MTCs
enhanced the rate of movement of fluorescent Ad2 to the nucleus
and increased the nuclear targeting efficiency of Ad2. We propose
that suppression of MT dynamics by low concentrations of MTCs
enhances MT-dependent trafficking toward the minus ends of MTs
and facilitates nuclear targeting.
M icrotubules (MTs) are regulated dynamic cytoskeletalpolymers, crucial for many important cellular functions,
including the spatial organization of the interphase cytoplasm,
cell signaling, and chromosome segregation in mitosis (1–3). In
most cells, MTs are organized in a single array with their minus
ends associated with the MT organizing center located near the
nucleus and their plus ends toward the cell periphery. Therefore,
MTs are uniquely positioned to transmit signals to and from the
nucleus and may play a central role in intracellular transport and
signal transduction (1). A wide variety of natural products,
including paclitaxel (PTX) and the vinca alkaloids, target MTs
and are widely used in cancer chemotherapy (4, 5). At high
concentrations, these MT-targeting compounds (MTCs) disrupt
normal MT function by either stabilizing or destabilizing MTs.
It has been shown that low doses of both MT-stabilizing or
-destabilizing drugs potently suppress MT dynamics without any
alterations in the MT polymer mass (6, 7). Suppression of MT
dynamics is important for the antimitotic action of these drugs,
because inhibition of MT dynamics results in kinetic stabilization
of the mitotic spindle leading to mitotic arrest (8, 9). However,
whether inhibition of MT dynamics without changes in the MT
polymer mass affects MT functions in interphase is currently
unknown.
We have recently shown that the tumor suppressor protein p53
associates with MTs and uses the MT-dependent motor complex
dyneinydynactin for nuclear targeting, e.g., after DNA damage
(10). Disruption of the MT network by polymerization with high
concentrations of PTX or depolymerization with vincristine
(VCR) impedes p53 translocation to the nucleus and in turn
inhibits activation of downstream targets by p53. Although an
intact MT network is required for p53 trafficking, the role of a
dynamic MT network for p53 nuclear accumulation is not
known.
Using low concentrations of PTX or VCR, we investigate
herein the effects of suppressing MT dynamics on the translo-
cation of p53 to the nucleus. We show that after treatment with
concentrations of PTX or VCR lower than those required to
affect polymerization, p53 nuclear accumulation is enhanced.
This accumulation was accompanied by induction of down-
stream targets of p53. In a cell line harboring wild-type (wt) p53
but a mutant b tubulin insensitive to PTX, nuclear targeting of
p53 by low concentrations of PTX did not occur. In addition, low
concentrations of PTX or nocodazole (Noc) enhanced the
nuclear targeting and the rate of movement of the human
adenovirus type 2 (Ad2), a nonenveloped virus that replicates
within the nucleus of an infected cell and uses MTs to traffic
from the cytoplasm to the nucleus (11). Our data demonstrate
that MT-mediated trafficking in interphase cells can be regu-
lated and enhanced above physiological levels. It is possible that
the manipulation of MT dynamics by MT-interacting compounds
can be exploited to enhance cell death in human cancer cells.
Materials and Methods
Cell Lines and Antibodies. Human lung cancer A549 cells were
obtained from the National Cancer Institute Drug Anticancer
Drug Screen and the human cervical cancer HeLa cells from
American Type Culture Collection. A2780 (1A9) human ovarian
carcinoma cells and their epothilone (Epo)-resistant subline,
A2780yEpo B, were a generous gift from Craig Fairchild (Bris-
tol-Myers Squibb). Mouse monoclonal antibodies against p53
(Ab 6: Mab Do1) and mdm2 (Ab-2) were purchased from
Oncogene Science. The sheep polyclonal antibody against p53
(Ab-7) was from Oncogene Science. The mouse monoclonal
anti-a-tubulin (DM1a) antibody and the rabbit polyclonal anti-
actin antibody were from Sigma. The antibody against the
cleaved epitope of poly(ADP-ribose)polymerase (PARP) (p85)
was from Upstate Biotechnology (Lake Placid, NY). PTX was
purchased from Bristol-Myers Squibb, VCR from Eli Lilly, and
colchicine, Noc, and adriamycin (ADR) were from Sigma.
Western and Northern Blot Analysis. Western blot analysis was
performed as previously described (10). Briefly, 30 mg of total
cell protein was resolved by 10% SDSyPAGE and immunoblot-
ted with the indicated antibodies. Northern blot analysis for the
p53-up-regulated modulator of apoptosis (PUMA) mRNA was
performed as previously described (12).
Abbreviations: MT, microtubule; MTC, MT-targeting compound; PTX, paclitaxel; VCR,
vincristine; ADR, adriamycin; Epo, epothilone; Noc, nocodazole; Ad2, adenovirus type 2;
Ad2-TR, Ad2 labeled with Texas red; PARP, poly(ADP-ribose)polymerase; PUMA, p53-
up-regulated modulator of apoptosis; CLSM, confocal laser scanning microscopy; ES, ele-
mentary motion steps; wt, wild type; p.i., postinfection.
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Immunofluorescence and Microscopy. Exponentially growing cells
were plated on 12-mm glass coverslips (A. Daigger, Vernon
Hills, IL) and incubated overnight. The next day, after drug
treatment, cells were fixed and processed for double immuno-
fluorescence labeling as previously described (10). The primary
antibodies used were the mouse monoclonal anti-a-tubulin
(DM1a) antibody for tubulinyMT staining and the sheep poly-
clonal (Ab-7) antibody for p53 staining. The coverslips were
examined on a Zeiss axioplasm microscope by using a Zeiss
100 3 1.3 oil immersion objective. Confocal images were ob-
tained on an LSM 510 laser scanning (Zeiss) microscope (Zeiss
axioplasm).
Time-Lapse Fluorescence Microscopy and Quantitative Subcellular
Analyses of Ad2-TR. Ad2 was isolated and labeled with the
fluorophore Texas red (Ad2-TR) (13). Infections of A549
human lung epithelial carcinoma cells that were pretreated or
not with the MT active drugs Noc (Sigma) and PTX (Sigma) at
low concentrations were carried out as described (14), except
that cold synchronization was omitted, and virus was added
directly to the cells in RPMI-BSA at 37°C for 10 min (about 2,000
particles per cell). Cells were washed with warm DMEM-BSA
and further incubated at 37°C as indicated. Under these condi-
tions, 50–100 particles were bound per cell, independent of the
pretreatments with Noc or Taxol. Virus motility was analyzed by
live-mode video microscopy and the elementary motion steps as
well as motility frequencies determined exactly as described (11).
Population velocities were calculated from the net distance
traveled to and from the nucleus divided by the total time of
sampling of the analyzed particles (n). Population motilities
represented the mean number of elementary motion steps (ES)
larger than 0.1 mmzs21 divided by the total number of ES of each
particle. Motilities c and p were defined as the average fractions
of the vectorial ES components larger than 0.1 mmzs21 directed
toward the center or the periphery. P values were determined by
using one-sided t tests. Quantifications of Ad2-TR in subcellular
regions of fixed cells were as described (13), and one-sided t tests
were applied as indicated.
Results
Low Concentrations of PTX or VCR Enhance p53 Nuclear Accumulation
and Result in Transcriptional Activation of mdm2. To assess the
effects of the MT-stabilizing drug PTX and the MT-destabilizing
drug VCR on p53 cellular localization, A549 human lung
carcinoma cells (with wt p53) were treated with low (6 nM) and
high (100 nM) concentrations of each drug for 18 hr. At low
concentrations, both the MT-stabilizing drug PTX and the
MT-destabilizing drug VCR cause suppression of MT dynamics
(4, 8, 9, 15–17). The subcellular localization of p53 was moni-
tored by indirect immunofluorescence followed by confocal laser
scanning microscopy (CLSM; Fig. 1A). Cells treated with the
DNA-damaging drug ADR readily accumulated p53 in the
nucleus, as expected (18). Treatment with 6 nM PTX or 6 nM
VCR (without ADR) resulted in enhanced p53 nuclear accu-
mulation (red p53 staining), similar to the ADR-treated cells. In
agreement with previous reports (17, 19), these low concentra-
tions of PTX and VCR had no apparent effects on MTs or the
organization of the MT network (Fig. 1 A and Fig. 6, which is
published as supporting information on the PNAS web site,
www.pnas.org). In contrast, treatment with higher PTX concen-
trations (100 nM) resulted in extensive stabilization of MTs, as
evidenced by tubulin bundling, whereas treatment with 100 nM
VCR resulted in MT depolymerization (Fig. 1 A). In agreement
with our previous findings, interference with the MT network by
either hyperstabilization with PTX (100 nM) or depolymeriza-
tion with VCR (100 nM) impaired p53 nuclear accumulation.
Consistent with this finding, low concentrations of PTX (3–25
nM) enhanced p53 nuclear accumulation and induced mdm2, a
surrogate marker of p53 nuclear accumulation (Fig. 1B). Higher
doses of PTX (50 and 100 nM), however, failed to induce mdm2,
consistent with a lack of p53 in the nucleus. Similar to the PTX
treatment, 3–12 nM VCR resulted in induction of mdm2,
whereas higher concentrations had no effect on mdm2 expres-
sion levels, consistent with the loss of the MT network and a lack
of p53 nuclear accumulation. To investigate whether the above
findings were specific to the A549 human lung carcinoma cells,
we performed a similar experiment by using the A2780 (1A9)
human ovarian carcinoma cells containing wt p53 (20). The
results confirmed the enhanced p53 nuclear accumulation seen
after treatment with low concentrations of either PTX or VCR
(Fig. 2 A and B).
P53 Nuclear Accumulation by MTCs Requires DrugyTubulin Interaction.
We next tested whether the effects of low concentrations of PTX
and VCR on p53 nuclear accumulation were MT dependent. We
used a subclone of A2780 cells (A2780yEpo B) that harbors an
acquired b tubulin mutation at residue Arg-282 to Gln (R282Q).
This mutation is located near the taxane-binding site on tubulin
(21). It impairs the PTXytubulin interaction, thus conferring 10-
to 15-fold crossresistance to PTX, but has no effect on VCR’s
interaction with tubulin (22). Treatment of A2780yEpo B cells
with 3 nM PTX had no effect on p53 nuclear accumulation,
whereas treatment with 3 nM VCR resulted in increased p53
nuclear accumulation (Fig. 2C). As expected, 100 nM VCR
resulted in the complete depolymerization of the MT network
and did not enhance p53 nuclear accumulation. Interestingly,
treatment with 100 nM PTX slightly increased p53 nuclear
staining in A2780yEpo B cells. This observation is in agreement
Fig. 1. (A) Low concentrations of PTX or VCR enhance p53 nuclear accumu-
lation in A549 cells. A549 cells were treated with the indicated drugs for 18 hr
and processed for double immunofluorescence labeling with antibodies
against p53 (red, labeled with Rhodamine red X) or a-tubulin (green, labeled
with FITC). Untreated A549 cells were included as control (CTRL). Staining was
analyzed by CLSM. (Bar 5 10 mm.) (B) Low concentrations of PTX or VCR induce
mdm2 in A549 cells. Untreated A549 cells (0) or cells treated for 18 hr were
processed for Western blotting. Cells treated with 400 ngyml of ADR for 18 hr
are included as a positive control for p53 and mdm2 increased levels. Thirty
micrograms of total cellular protein from each sample were resolved in a 10%
SDSyPAGE, transferred, and immunoblotted with antibodies against p53 and
mdm2. Please notice that in the Westerns blots shown here, the control lane
(CTRL) has been moved from the first position to the second to facilitate the
direct comparison of the control lane with the ADR lane to the right and the
PTX 3 lane to the left.
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with the impaired PTXytubulin interaction. As a consequence,
much higher concentrations of PTX are required to mimic the
effect of low PTX concentrations in a wt cell line. Together,
these results suggest that suppression of MT dynamics by low
concentrations of MTCs enhances the nuclear accumulation of
p53 and activates the p53 target gene, mdm2.
Low Concentrations of Other MT-Interacting Compounds Enhance p53
Nuclear Accumulation. To further test the above hypothesis, the
effects of other MT-stabilizing compounds, Epo A and B, or
destabilizing compounds, Noc and colchicine, on p53 nuclear
accumulation were examined. The results shown in Fig. 3 A and
B reveal that treatment of A549 cells with a low concentration
(3 nM) of each of these compounds enhanced p53 nuclear
accumulation (Fig. 3A, red p53 staining) and increased the
transactivation of mdm2 (Fig. 3B).
MT-Mediated Trafficking of Ad2 Is Enhanced by Low Concentrations of
PTX or Noc. We next sought to investigate the effects of low
concentrations of MTCs on the intracellular trafficking of the
human Ad2. Like other viral pathogens (23), this virus replicates
in the nucleus and utilizes the MT-dependent dyneinydynactin
motor complex for targeting to the MT minus ends, typically
located near the nuclear membrane (11). The motility of incom-
ing virus is biased to the nucleus because of virus-induced cell
signaling (24). The activation of an integrin–PKA pathway peaks
at 15 min postinfection (p.i.), and the induction of the MKK6-
p38yMAKP-MK2 module peaks at 30 min p.i. Minus-end-
directed Ad2 transport is more efficient in cells expressing the
MT-binding domain of the MT-associated protein MAP4 (11),
which confers enhanced MT stability (25). We therefore tested
whether the suppression of MT dynamics with low concentra-
tions of MTCs facilitated MT-dependent Ad2 trafficking. A549
cells were treated with 1 nM PTX or Noc for 18 hr before
infection with Ad2-TR. The intracellular localization of the
labeled virus was quantified at 15 and 40 min p.i., i.e., before and
after the onset of Ad-induced signaling affecting the MT-
dependent transport rates (Fig. 4A). Enhanced Ad2-TR nuclear
and perinuclear accumulation was observed in the presence of 1
nM PTX or 1 nM Noc at 15 min p.i., compared with the
nontreated cells (P , 0.01 for PTX and 0.05 for Noc). This
enhanced nuclear targeting of Ad2-TR was accompanied by a
more rapid clearance of the periphery in drug-treated cells
compared with nontreated cells (P , 0.01 for both drugs; Fig. 4A
and Fig. 7, which is published as supporting information on the
PNAS web site). Enhanced nuclear targeting of Ad2-TR by 1 nM
PTX or 1 nM Noc was also measured by video microscopy (Fig.
4B). Until 20 min p.i., the population motility of Ad2 toward the
nucleus was enhanced by both PTX and Noc by a factor of 3
Fig. 2. Low concentrations of PTX or VCR enhance p53 nuclear accumula-
tion, and induce mdm2 in A2780 (1A9) cells in a tubulin-dependent manner.
1A9 cells were plated in duplicate, subjected to the indicated drug treatments,
and processed either for CLSM (A) or Western blotting (B). (A) Cells are stained
with antibodies against p53 (red, labeled with Rhodamine red X) or a-tubulin
(green, labeled with FITC). (Bar 5 10 mm.) (B) Thirty micrograms of total cell
protein from each sample were resolved in a 10% SDSyPAGE, transferred, and
immunoblotted with antibodies against p53 and mdm2. Induction of mdm2 is
consistent with enhanced p53 nuclear accumulation (A). (C) The b tubulin
mutant A2780yEpo B cells were treated with the indicated drugs for 18 hr and
processed for double immunofluorescence labeling with antibodies against
p53 (red, labeled with Rhodamine red X) or a-tubulin (green, labeled with
FITC). Untreated A2780yEpo B cells (CTRL) and cells treated with ADR are
included as controls. Staining was analyzed by CLSM. (Bar 5 10 mm.)
Fig. 3. Low concentrations of other MT-active agents enhance p53 nuclear
accumulation and induce mdm2 in A549 cells. A549 cells were plated in
duplicate, subjected to the indicated drug treatments, and processed either
for CLSM (A) or Western blotting (B) (see Fig. 2). Arrows in A point to either
bundled MTs (Epo A, Epo B) or depolymerized tubulin network (colchicine,
Noc). (Bar 5 10 mm.)
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compared with nontreated cells and reached 0.09 mmymin (Fig.
4B Upper, and Movies 1–6, which are published as supporting
information on the PNAS web site). This enhanced motility was
largely because of augmented minus-end-directed velocities of
individual elementary motion steps. Interestingly, the frequen-
cies of both minus-end- and plus-end-directed motilities were
both reduced by PTX and Noc, consistent with the notion that
low concentrations of PTX and Noc reduce, e.g., the motility of
peripheral phagosomes (26). After the onset of MT-directed
signaling by Ad2 (i.e., 20–50 min p.i.), we did not observe any
significant differences in the population speeds of Ad2-TR in
PTX- or Noc-treated cells compared with control cells (Fig. 4B
Lower). This observation was consistent with the subcellular
localizations of Ad2-TR at 40 min p.i. (Fig. 4A Lower). In
addition, enhanced nuclear targeting of Ad2-TR early in infec-
tion was also obtained with a different cell line (HeLa) treated
with 1 nM Noc (Fig. 8, which is published as supporting
information on the PNAS web site). These data demonstrate that
low concentrations of MTCs enhanced MT-mediated minus-
end-directed trafficking of Ad2.
Potentiation of Apoptotic Cell Death in Cells Treated with Low
Concentrations of PTX or VCR Followed by ADR. Because p53 exerts
many of its effects by transcriptional regulation (27), its trans-
location from cytoplasmic sites of synthesis to nuclear target
genes is critical to elicit biological responses. To further inves-
tigate the biological effects of enhanced p53 nuclear targeting by
low doses of MTCs, we performed the experiment shown in Fig.
5. A549 cells were first treated with 3, 6, or 100 nM of either PTX
(Fig. 5A) or VCR (Fig. 5B) for 18 hr and then exposed to ADR
(200 ngyml) for another 6 hr. When 3 or 6 nM of each drug
was combined with ADR (PTX33ADR, PTX63ADR,
VCR33ADR, and VCR63ADR), apoptosis was observed. As
a marker of apoptosis, the p85 cleaved epitope of poly(ADP-
ribose)polymerase (PARP) (exposed only after it is cleaved in
cells undergoing apoptosis) was detected (28). The results with
PARP cleavage were confirmed with caspase-3 activation assay
and the sulforhodamine-B cell survival assay (Fig. 9, which is
published as supporting information on the PNAS web site).
Although lower concentrations of MTCs did not induce
caspase-3 activation and were only marginally cytotoxic, they
rendered cells sensitive to posttreatment with ADR (Fig. 9). In
the samples where PARP cleavage was observed (PTX33ADR,
PTX63ADR, VCR33ADR, and VCR63ADR), induction of
p53 and mdm2 was also observed. This finding is consistent with
enhanced p53 nuclear accumulation and activation of apoptotic
responses (29). Although treatment with higher concentrations
of PTX (100 nM) alone or in combination with ADR induced
PARP cleavage, it did not increase p53 or mdm2 levels. Similar
results were observed with high concentrations of VCR. These
results suggest that, at higher drug concentrations, MTCs induce
cell death independently of p53-nuclear targeting. To further
tighten the correlation between enhanced p53 nuclear accumu-
lation and p53-mediated apoptosis, we performed a Northern
blot analysis for a recently identified p53 target gene, the PUMA
(Fig. 5C). PUMA is induced by both high levels of exogenous p53
and elevated endogenous p53 and results in apoptosis (12, 30).
Increased PUMA levels were observed in cells treated with
PTX33ADR or PTX63ADR but not with PTX100 or
PTX1003ADR, suggesting that the apoptosis induced by high
concentrations of PTX is p53-independent. These data confirm
and extend the notion that low concentrations of MTCs enhance
p53 nuclear accumulation and lead to apoptosis on short expo-
sure to ADR.
Fig. 4. Low concentrations of PTX or Noc enhance the nuclear targeting and
the motility of Ad2 in A549 cells. (A) Untreated A549 cells (mock) or cells
treated with 1 nM Noc or 1 nM PTX (Tax) for 18 hr were infected with Ad2-TR
in RPMI-BSA at 37°C. In randomly selected untreated or drug-treated cells, the
nuclear, perinuclear, cytoplasmic, and peripheral fluorescence of Ad2-TR was
quantitated 15 min (Upper) or 40 min (Lower) p.i. The bars represent the
average of fluorescence 6 SEM of 20–40 independent measurements. (B)
Untreated A549 cells (no drug) or cells treated with 1 nM of either PTX (Tax)
or Noc for 18 hr were infected with Ad2-TR in RPMI-BSA at 37°C for 15 min
followed by further incubation in RPMI-BSA in the presence of PTX or Noc but
without the virus until imaging of Ad2-TR was completed. Ad2-TR was imaged
in time-lapse mode, and ES were analyzed for each viral particle at 0–20 min
(Upper) or 20–50 min (Lower) p.i. Population motilities (pop mot) represent
the mean number of ES larger than 0.1 mmys divided by the total of ES of each
particle. Mot c and mot p were defined as the average fractions of the vectorial
ES components larger than 0.1 mmys directed toward the cell center (mot c)
and toward the cell periphery (mot p), including the SEM and P values. For all
measurements, (2) indicates motility toward the cell’s center.
Fig. 5. Treatment with low concentrations of PTX or VCR followed by ADR
enhances apoptosis in A549 cells. (A) A549 cells were treated with 3, 6, or 100
nM of PTX or VCR for 18 hr followed by treatment with 200 ngyml of ADR for
an additional 6 hr (PTX33ADR, PTX63ADR, PTX1003ADR, and VCR33ADR,
VCR63ADR, VCR1003ADR). ADR was added to the medium containing PTX
or VCR at the indicated concentrations. Untreated cells (CTRL) or cells treated
with 200 ngyml of ADR alone (ADR), PTX alone, or VCR alone for 24 hr (PTX3,
PTX6, PTX100; VCR3, VCR6, VCR100) were included as controls. Western blots
were probed with antibodies against the cleaved (p85) form of PARP, p53,
mdm2, and actin as a loading control. (B) A549 cells were treated with 3, 6, or
100 nM PTX for 18 hr, followed by treatment with 200 ngyml of ADR for an
additional 6 hr (PTX33ADR, PTX63ADR, PTX1003ADR). Untreated cells
(CTRL) or cells treated with PTX alone for 24 hr (PTX3, PTX6, PTX100) are
included as controls. Ten micrograms of total RNA from each sample were
analyzed by Northern blotting. Ethidium bromide staining of 28S RNA is
shown as loading control.
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Discussion
We have previously shown that the tumor suppressor protein p53
is associated with the MT cytoskeleton and, in response to DNA
damage, is transported toward the nucleus via the minus-end
MT-associated motor protein dynein (10).
MT dynamics are essential for many MT-dependent cellular
processes and in particular for mitosis, which is very sensitive to
alteration of MT dynamics (4, 31–33). Both MT-stabilizing and
-destabilizing agents at very low concentrations potently suppress
MT dynamics, leading to kinetic stabilization of the mitotic spindle
(8, 9, 15, 17). In addition, MTs provide tracks or scaffolds for the
directional vesicle transport as well as organelle positioning.
We propose that suppressing the dynamics of interphase MTs
may actually enhance their functions in transporting molecules.
We demonstrate here that low concentrations of PTX or VCR
(3 and 6 nM) enhance the nuclear accumulation of p53 and
induce activation of the p53-dependent gene, mdm2. Further-
more, we showed that p53 nuclear accumulation depended on
the ability of MTCs to bind tubulin, as evidenced by the lack of
response of a cell line with a mutant b tubulin (R282Q mutation
located at the PTX-binding pocket) to low doses of PTX. These
findings favor the notion that suppression of MT dynamics leads
to enhanced p53 nuclear targeting and is in concert with
published reports showing that very low concentration of MTCs,
well within the range of concentrations we used in this report,
suppress MT dynamics both in vitro and in cells (4, 8, 9, 15, 17).
More specifically, a recent study reported that treatment of A549
cells with as little as 2 nM PTX overnight was sufficient to
suppress the overall dynamicity of MTs by 30% (34).
If suppression of MT dynamics affects MT-dependent cellular
transport, it should not be limited to p53 but should apply to
other entities that use MT-dependent transport. One such entity
is the human common Ad2. The MT-dependent nature of Ad2
movement within the cell made it an ideal system to test the
effects of suppressing MT dynamics by low concentrations of
MTCs on Ad2 transport along MTs. Enhanced Ad2 nuclear and
perinuclear accumulation was observed in A549 cells treated
with 1 nM PTX or Noc compared with untreated cells (Fig. 4 and
Figs. 7 and 8). Treated cells also demonstrated increased minus-
end-directed population motilities of Ad2 (Fig. 4 and Movies
1–3). These observations from both the static and the dynamic
analyses of Ad movement were limited to the early stages of
infection (0–20 min p.i.). At later stages, no significant differ-
ences were observed between treated and untreated cells. The
positive effect of MTCs on Ad2 nuclear targeting early in
infection correlates with the absence of Ad-induced signaling
known to stimulate nuclear targeting at 20 min p.i. (24). It also
correlates with the enhanced nuclear targeting of Ad2 in cells
where MTs are stabilized by overexpression of the MT-binding
domain of MAP4 (MT-associated protein 4) (11). This corre-
lation raises the possibility that the MT-stabilizing effects of
MAPs and the suppression of MT dynamics by low concentra-
tions of MTCs could elicit similar cellular effects, such as
enhanced MT-dependent transport. At later stages of infection,
we see no difference in the nuclear targeting of Ad2 between
treated and untreated cells, possibly because Ad-induced signals
boosting the perinuclear and nuclear accumulation of the virus
mask the effects of suppressing MT dynamics in intracellular
trafficking.
The involvement of MTs in signal transduction and the
relationship between MTs and transcription factors in human
cancer have only recently started to attract attention (for re-
views, see refs. 1 and 35). For example, p53 function depends on
its nuclear localization, and both p53 nuclear import and export
are cellular processes tightly regulated (36). We showed here that
enhanced p53 nuclear accumulation with low concentrations of
PTX or VCR before short exposure to low concentrations of
ADR resulted in apoptotic cell death in A549 cells, as evidenced
by the induction of PARP cleavage and caspase-3 activation.
This finding may be important in a clinical setting, as the taxanes
are often combined with ADR or radiation for the treatment of
different types of cancer (37, 38). Our findings demonstrate that
pretreatment with low concentrations of MTCs (which do not
induce either mitotic arrest or change tubulin polymerization)
sensitizes cells to the effects of ADR, including induction of
PUMA and apoptosis. This effect may be the result of additive
phosphorylation of p53, as MTCs and DNA damage have been
shown to induce p53 phosphorylation at distinct residues (39).
In addition, p21 induction by the enhanced p53 nuclear accu-
mulation has been shown to inhibit topoisomerase genes (38),
which might cooperate with ADR-mediated inhibition of
topoisomerase.
Our results demonstrate that drugs like PTX alter p53 nuclear
trafficking at therapeutically relevant drug exposure and that
combination therapies with known p53-dependent agents such
as ADR can be potentiated by p53-enhancing concentrations of
PTX. This conclusion supports the notion that lower doses of
MTC can be therapeutically more attractive than higher doses
(39). Finally, although disruption of MT functions by MTCs is
well known and is the basis of mitosis arrest and of inhibition of
MT-mediated trafficking, very low concentrations of MTCs can
increase some functions of MTs in interphase cells. This is the
first demonstration, to our knowledge, that MT-mediated traf-
ficking can be pharmacologically increased.
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